Gwenn Hansen Sells 5,394 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $107,880.00. Following the sale, the insider directly owned 115,005 shares of the company’s stock, valued at $2,300,100. This trade represents a 4.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, April 30th, Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.65, for a total value of $53,513.10.

Nurix Therapeutics Price Performance

Shares of NRIX traded up $3.16 during mid-day trading on Thursday, reaching $22.46. The company’s stock had a trading volume of 5,326,252 shares, compared to its average volume of 1,513,415. Nurix Therapeutics, Inc. has a 12-month low of $8.19 and a 12-month high of $23.09. The stock has a market cap of $2.32 billion, a PE ratio of -7.11 and a beta of 1.86. The company’s 50 day moving average is $16.74 and its 200 day moving average is $16.96.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.03). The business had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Jefferies Financial Group upped their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Wells Fargo & Company cut shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and reduced their price target for the company from $28.00 to $25.00 in a research report on Monday, June 8th. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 10th. Robert W. Baird raised their price objective on Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, BTIG Research lifted their target price on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.20.

Hedge Funds Weigh In On Nurix Therapeutics

A number of hedge funds have recently modified their holdings of the business. Larson Financial Group LLC boosted its stake in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics during the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Nurix Therapeutics during the fourth quarter worth about $33,000. KBC Group NV acquired a new position in Nurix Therapeutics in the 1st quarter valued at about $34,000. Finally, Wexford Capital LP acquired a new position in Nurix Therapeutics in the 3rd quarter valued at about $41,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.